uridine has been researched along with capuramycin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, M; Enokita, R; Inukai, M; Ishii, MM; Kizuka, M; Muramatsu, A; Muramatsu, Y; Ogawa, Y; Ohnuki, T; Suzuki, T; Takatsu, T; Tsutsumi, S | 1 |
| Inukai, M; Ishii, MM; Muramatsu, Y | 1 |
| Arai, M; Inukai, M; Ishii, MM; Miyakoshi, S; Muramatsu, Y; Ogawa, Y; Ohnuki, T; Takatsu, T | 1 |
| Inukai, M; Miyakoshi, S; Muramatsu, Y; Ohnuki, T; Takatsu, T | 1 |
| Walsh, CT; Zhang, W | 1 |
| Franzblau, SG; Kurosu, M; Mitachi, K; Siricilla, S; Wan, B | 1 |
| Baba, S; Barnard-Britson, S; Cai, W; Ducho, C; Funabashi, M; Garneau-Tsodikova, S; Goswami, A; Green, KD; Liu, X; Morris, AJ; Nonaka, K; Spork, AP; Sunkara, M; Thorson, JS; Van Lanen, SG; Yang, Z | 1 |
| Bogatcheva, E; Einck, L; Guerrant, RL; Kolling, GL; Moore, JH; Nikonenko, B; Phipps, AJ; Protopopova, M; Shin, JH; van Opstal, E; Warren, CA | 1 |
8 other study(ies) available for uridine and capuramycin
| Article | Year |
|---|---|
Studies on novel bacterial translocase I inhibitors, A-500359s. I. Taxonomy, fermentation, isolation, physico-chemical properties and structure elucidation of A-500359 A, C, D and G.
Topics: Aminoglycosides; Anti-Bacterial Agents; Azepines; Bacteria; Enzyme Inhibitors; Fermentation; Magnetic Resonance Spectroscopy; Molecular Structure; Stereoisomerism; Streptomyces; Transferases (Other Substituted Phosphate Groups); Uridine | 2003 |
Studies on novel bacterial translocase I inhibitors, A-500359s. II. Biological activities of A-500359 A, C, D and G.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Azepines; Bacteria; Enzyme Inhibitors; Kinetics; Mice; Microbial Sensitivity Tests; Mycobacterium smegmatis; Transferases (Other Substituted Phosphate Groups); Uridine | 2003 |
Studies on novel bacterial translocase I inhibitors, A-500359s. III. Deaminocaprolactam derivatives of capuramycin: A-500359 E, F, H; M-1 and M-2.
Topics: Aminoglycosides; Anti-Bacterial Agents; Azepines; Bacteria; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Molecular Structure; Spectrophotometry, Ultraviolet; Transferases (Other Substituted Phosphate Groups); Uridine | 2003 |
Studies on novel bacterial translocase I inhibitors, A-500359s. IV. Biosynthesis of A-500359s.
Topics: Aminoglycosides; Anti-Bacterial Agents; Azepines; Enzyme Inhibitors; Fermentation; Magnetic Resonance Spectroscopy; Molecular Structure; Transferases (Other Substituted Phosphate Groups); Uridine | 2003 |
Chemical logic and enzymatic machinery for biological assembly of peptidyl nucleoside antibiotics.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; Bacterial Proteins; Nucleosides; Peptides; Pyrimidine Nucleosides; Transferases; Transferases (Other Substituted Phosphate Groups); Uridine | 2011 |
Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.
Topics: Aminoglycosides; Antitubercular Agents; Bacterial Proteins; Caprolactam; DNA-Directed RNA Polymerases; Drug Synergism; Enzyme Inhibitors; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxygen; Structure-Activity Relationship; Transferases; Transferases (Other Substituted Phosphate Groups); Uridine | 2015 |
The Biosynthesis of Capuramycin-type Antibiotics: IDENTIFICATION OF THE A-102395 BIOSYNTHETIC GENE CLUSTER, MECHANISM OF SELF-RESISTANCE, AND FORMATION OF URIDINE-5'-CARBOXAMIDE.
Topics: Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Heme; Kinetics; Magnetic Resonance Spectroscopy; Molecular Sequence Data; Multigene Family; Open Reading Frames; Phosphorylation; Polymerase Chain Reaction; Protein Binding; Recombinant Proteins; Streptomyces; Threonine; Transaldolase; Uridine; Uridine Monophosphate | 2015 |
Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.
Topics: Administration, Oral; Aminoglycosides; Animals; Anti-Bacterial Agents; Bacterial Shedding; Bacterial Toxins; Clostridioides difficile; Disease Models, Animal; Enterocolitis, Pseudomembranous; Feces; Male; Mice, Inbred C57BL; Severity of Illness Index; Survival Analysis; Treatment Outcome; Uridine | 2016 |